Finding Optimal Scan Timing for Sickle Cell Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
UPMC, Pittsburgh, PASickle Cell DiseasePositron Emission Tomography - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trialwill study if PET imaging can detect VOC in SCD patients, allowing us to better understand and treat VOCs in the future.

Eligible Conditions
  • Sickle Cell Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Computed Tomography
1
Multiparametric Magnetic Resonance Imaging Scan
1
Positron emission tomography/computed tomography scan

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Up to five years from first assessment depending on when VOC occurs.

Hour 2
Association of PET tracer uptake with intensity of pain in VOC
Up to five years from first assessment depending on when VOC occurs.
Change in PET tracer uptake in VOC
Day 5
Association of PET tracer uptake with clinical VOC markers

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Computed Tomography
1
Multiparametric Magnetic Resonance Imaging Scan
1
Positron emission tomography/computed tomography scan

Trial Design

2 Treatment Groups

Finding Optimal Scan Timing
1 of 2
Scan at Determined Optimal Timepoint
1 of 2

Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: Finding Optimal Scan Timing · No Placebo Group · Phase 1

Finding Optimal Scan TimingExperimental Group · 2 Interventions: Positron Emission Tomography, Cu-64]-LLP2A · Intervention Types: Radiation, Drug
Scan at Determined Optimal TimepointExperimental Group · 2 Interventions: Positron Emission Tomography, Cu-64]-LLP2A · Intervention Types: Radiation, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography
2008
Completed Phase 2
~2800

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to five years from first assessment depending on when voc occurs.

Who is running the clinical trial?

Enrico M NovelliLead Sponsor
1 Previous Clinical Trials
30 Total Patients Enrolled
The Pittsburgh FoundationOTHER
3 Previous Clinical Trials
219 Total Patients Enrolled
Enrico Novelli, MD, MSPrincipal InvestigatorUniversity of Pittsburgh

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

Are there any recruitment opportunities for individuals to partake in this research?

"Clinicaltrials.gov confirms the continued recruitment for this trial which was inaugurated on November 11th 2022 and recently modified on December 2nd 2022." - Anonymous Online Contributor

Unverified Answer

How many people are eligible to participate in this clinical trial?

"Affirmative. Based on information hosted on clinicaltrials.gov, this medical study is still recruiting participants as of December 2nd 2022 when it was last updated. The original post date for the trial was November 11th 2020 and only 20 patients need to be recruited at one site." - Anonymous Online Contributor

Unverified Answer

Has the FDA provided authorization for Scan at Determined Optimal Timepoint?

"Taking into consideration the Phase 1 status of this drug, Power has attributed a score of 1 to Scan at Determined Optimal Timepoint's safety profile. This rating is based on limited evidence that supports both efficacy and security." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top